Compare FNF & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNF | DVA |
|---|---|---|
| Founded | 1847 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 14.9B |
| IPO Year | 2005 | 2003 |
| Metric | FNF | DVA |
|---|---|---|
| Price | $43.96 | $173.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | $54.75 | ★ $222.29 |
| AVG Volume (30 Days) | ★ 2.6M | 814.1K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 4.34 | ★ 10.27 |
| Revenue | ★ $14,445,000,000.00 | $13,643,069,000.00 |
| Revenue This Year | N/A | $4.44 |
| Revenue Next Year | $0.68 | $3.53 |
| P/E Ratio | ★ $10.23 | $16.96 |
| Revenue Growth | 5.58 | ★ 6.46 |
| 52 Week Low | $37.88 | $101.00 |
| 52 Week High | $59.99 | $247.49 |
| Indicator | FNF | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 40.58 |
| Support Level | $42.78 | $172.84 |
| Resistance Level | $46.88 | $197.83 |
| Average True Range (ATR) | 1.41 | 7.00 |
| MACD | 0.24 | -1.78 |
| Stochastic Oscillator | 64.85 | 7.09 |
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. All of the company's revenue is generated in the United States.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.